» Articles » PMID: 27372056

The Prevalence and Treatment Patterns of Diabetes in the Greek Population Based on Real-world Data from the Nation-wide Prescription Database

Overview
Specialty Endocrinology
Date 2016 Jul 4
PMID 27372056
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Epidemiological data regarding diabetes in Greece are based on regional, small-scale studies. We aimed to identify all citizens with prescribed pharmacological treatment for diabetes, to further explore type 1 diabetes prevalence and describe pharmacological treatment patterns in type 2 diabetes.

Methods: The electronic prescription database of the National Organization for Health Care Services Provision was used to identify individuals who received at least two prescriptions with an ICD-10 code relevant to diabetes, dispensed between June 1st, 2014 and May 31st, 2015. Type-1 diabetes was defined in those receiving at least two fully-reimbursable insulin prescriptions with an ICD-10 code of E10 (insulin-dependent diabetes).

Results: The study population consisted of 10,222,779 individuals, accounting for 95% of the Greek population. Prevalence of medication-prescribed diabetes was 7.0% (720,764 individuals), ranging from 0.08% in children and adolescents, to 8.2% in adults, and 30.3% in those ⩾75years old. Prevalence of type 1 diabetes was 0.24%, with a clear male predominance and more than half of cases developing after 14years of age. Metformin was the most frequently prescribed medication (77.4%) in type-2 diabetes followed by DPP-4 inhibitors (44.8%) and sulphonylureas (34.5%), while insulin was used by 19.4% of patients.

Conclusions: This nation-wide real-world data analysis on medication-prescribed diabetes demonstrates that the current prevalence in Greece is 7.0%, with wide age variation and high figures in older adults. Identification of pharmacological patterns among patients with type 2 diabetes is a valuable guide in policy-makers' efforts to balance a cost-effective, quality-acceptable disease management.

Citing Articles

Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database.

Terentes-Printzios D, Dima I, Benardos P, Mitrou P, Mathioudakis K, Tsolakidis A Int J Cardiol Cardiovasc Risk Prev. 2024; 21:200261.

PMID: 38623144 PMC: 11017038. DOI: 10.1016/j.ijcrp.2024.200261.


Rationale and Design of Heart Failure Prevalence and Evolution of Heart Failure in Diabetes Mellitus Type II Patients at High Risk (HF-LanDMark Study).

Parissis J, Georgiou C, Bistola V, Karavidas A, Vassilikos V, Kanakakis J J Clin Med. 2023; 12(19).

PMID: 37834963 PMC: 10573953. DOI: 10.3390/jcm12196319.


Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece.

Bakirtzis C, Nikolaidis I, Boziki M, Grigoriadou E, Karakasi M, Moysiadis T Int J MS Care. 2023; 25(4):140-144.

PMID: 37469336 PMC: 10353693. DOI: 10.7224/1537-2073.2022-046.


Lifestyle Trajectories Are Associated with Incidence of Cardiovascular Disease: Highlights from the ATTICA Epidemiological Cohort Study (2002-2022).

Damigou E, Kouvari M, Chrysohoou C, Barkas F, Kravvariti E, Pitsavos C Life (Basel). 2023; 13(5).

PMID: 37240787 PMC: 10222365. DOI: 10.3390/life13051142.


CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.

Ghetti G, Pradelli L, Papageorgiou G, Karpouzos G, Arikan Y Clinicoecon Outcomes Res. 2023; 15:97-109.

PMID: 36825076 PMC: 9942503. DOI: 10.2147/CEOR.S400522.